These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19620476)

  • 1. Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma.
    Mohr P; Hauschild A; Trefzer U; Weichenthal M
    J Clin Oncol; 2009 Aug; 27(24):e70; author reply e71. PubMed ID: 19620476
    [No Abstract]   [Full Text] [Related]  

  • 2. Cognitive function and quality of life in interferon therapy for melanoma.
    Bender CM; Yasko JM; Kirkwood JM; Ryan C; Dunbar-Jacob J; Zullo T
    Clin Nurs Res; 2000 Aug; 9(3):352-63. PubMed ID: 11276624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients.
    Rataj D; Jankowiak B; Krajewska-Kułak E; Van Damme-Ostapowicz K; Nowecki ZI; Rutkowski P; Niczyporuk W
    Cancer Nurs; 2005; 28(3):172-8. PubMed ID: 15915059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
    Moschos SJ; Kirkwood JM; Konstantinopoulos PA
    J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613
    [No Abstract]   [Full Text] [Related]  

  • 5. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
    Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
    Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b.
    Brandberg Y; Aamdal S; Bastholt L; Hernberg M; Stierner U; von der Maase H; Hansson J
    Eur J Cancer; 2012 Sep; 48(13):2012-9. PubMed ID: 22196968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.
    Agarwala SS; Gray RJ; Wong MK
    J Clin Oncol; 2009 Sep; 27(25):e82-3; author reply e84. PubMed ID: 19635995
    [No Abstract]   [Full Text] [Related]  

  • 8. [After removal of a malignant melanoma. Enhancing the immune system!].
    MMW Fortschr Med; 1999 Nov; 141(44):66. PubMed ID: 10912153
    [No Abstract]   [Full Text] [Related]  

  • 9. Update on adjuvant interferon therapy for high-risk melanoma.
    Agarwala SS; Kirkwood JM
    Oncology (Williston Park); 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197. PubMed ID: 12380946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early signs of liver failure after low-dose interferon alfa-2b for cutaneous melanoma.
    Ammoury A; El Sayed F; Farah C; Bazex J
    J Am Acad Dermatol; 2008 Mar; 58(3):532-3. PubMed ID: 18280369
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant interferon in high-risk melanoma: end of the era?
    Janku F; Kurzrock R
    J Clin Oncol; 2010 Jan; 28(2):e15-6; author reply e17-8. PubMed ID: 19949007
    [No Abstract]   [Full Text] [Related]  

  • 12. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?
    Tarhini AA; Kirkwood JM
    J Clin Oncol; 2012 Nov; 30(31):3773-6. PubMed ID: 23008298
    [No Abstract]   [Full Text] [Related]  

  • 14. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.
    Cole BF; Gelber RD; Kirkwood JM; Goldhirsch A; Barylak E; Borden E
    J Clin Oncol; 1996 Oct; 14(10):2666-73. PubMed ID: 8874325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of cutaneous melanoma.
    Tsao H; Atkins MB; Sober AJ
    N Engl J Med; 2004 Sep; 351(10):998-1012. PubMed ID: 15342808
    [No Abstract]   [Full Text] [Related]  

  • 17. Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b.
    Kiley KE; Gale DM
    Clin J Oncol Nurs; 1998 Jan; 2(1):11-6. PubMed ID: 9481251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
    Moschos SJ; Edington HD; Land SR; Rao UN; Jukic D; Shipe-Spotloe J; Kirkwood JM
    J Clin Oncol; 2006 Jul; 24(19):3164-71. PubMed ID: 16809739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Complete remission of Crohn's disease after high-dose alpha-interferon treatment for malignant melanoma].
    Ferre Aracil C; Rodríguez de Santiago E; García García de Paredes A; Aguilera Castro L; Soria Rivas A; López SanRomán A
    Gastroenterol Hepatol; 2016; 39(6):397-400. PubMed ID: 26096290
    [No Abstract]   [Full Text] [Related]  

  • 20. [Recombinant interferon alfa-2b in the treatment of patients with skin melanoma].
    Korovin SI
    Lik Sprava; 1998; (2):139-41. PubMed ID: 9670687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.